These make billions, see any names?
"A number of antiviral vaccine strategies have also been developed that make use of nonreplicating immunogens, including inactivated viruses, recombinant proteins, and virus-like particles (VLPs). Chemical treatment or irradiation of a virus can eliminate the ability of that virus to replicate while leaving it in a conformation that can present protective epitopes to cells of the immune system. The currently used hepatitis A vaccine is such an immunogen. Viral proteins expressed in cell lines can also be administered as immunogens. The hepatitis B vaccine is based on this approach. Finally, the recently developed papillomavirus vaccine is a VLP, an immunogen created through the expression of structural viral proteins that come together in vitro to form nonreplicating, noninfectious particles. The inactivated virus-, recombinant protein-, and VLP-based vaccines all induce antibody and CD4+ T lymphocyte responses because these immunogens undergo MHC class II processing. However, because they do not replicate in vivo, these vaccine antigens do not undergo MHC class I processing and therefore do not elicit CD8+ T lymphocyte responses."
Letvin is talking about the next generation of vaccines and it is looking more and more like Bavi is characterizing at least a part of it.
News 
Market Data 
Discover 
